Welcome to our dedicated page for Inmed Pharmaceuticals SEC filings (Ticker: INM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading a biotech filing shouldn’t feel like deciphering a lab notebook. InMed Pharmaceuticals’ SEC reports are packed with clinical data, patent claims, and trial costs that can easily exceed two hundred pages. Whether you’re tracking cash burn before the next Phase 2 readout or watching management’s share purchases, the details matter—and they’re buried deep in the documents.
Stock Titan’s AI steps in where traditional search fails. Our platform parses every InMed annual report 10-K simplified, flags critical R&D footnotes in each InMed quarterly earnings report 10-Q filing, and delivers InMed Form 4 insider transactions real-time to your dashboard. Want the short version? Click for AI-powered summaries that explain trial milestones, licensing revenue, or dilution risk in plain language. Need to dig deeper? Every exhibit, amendment, and note is still one click away.
Here’s what you can uncover:
- Insider sentiment: Monitor InMed Pharmaceuticals insider trading Form 4 transactions and spot buying or selling before key announcements.
- Clinical progress: Use our tags on each InMed 8-K material events explained to see when new data or FDA feedback hits the wire.
- Governance clarity: Quickly locate stock option grants and bonus targets in the latest InMed proxy statement executive compensation.
- Financial runway: Compare quarter-over-quarter burn rates with our InMed earnings report filing analysis.
Stop scrolling through PDFs and start understanding InMed SEC documents with AI. From InMed executive stock transactions Form 4 to fresh S-3 shelf registrations, every filing type is here, updated the moment EDGAR releases it. Complex science, clear disclosures—now summarized for quicker, smarter decisions.
InMed Pharmaceuticals Inc. (Nasdaq: INM) has filed a Form S-1 to register 3.90 million common shares for resale by Sabby Volatility Warrant Master Fund Ltd. The shares represent 195% of INM’s 2.00 million shares outstanding as of 30 June 2025 and originate from a 24 June 2025 private placement that issued (i) 1.95 million pre-funded warrants (exercise price $0.0001) and (ii) 1.95 million preferred investment options (exercise price $2.436). INM will not receive proceeds from the resale, but could collect ≈$4.76 million if all preferred investment options are exercised for cash and $195 upon cash exercises of the pre-funded warrants.
The filing outlines INM’s capital structure: after assuming full exercise of the registered securities, common shares would rise to 5.91 million. Additional dilution remains possible from 2.59 million other warrants/options outstanding, including 126,904 placement-agent options issued to H.C. Wainwright and 199,115 repriced options held by Sabby (exercise price reduced from $16.60 to $2.436).
Financial position & need for capital: INM posted FY-2024 and FY-2023 net losses of $7.7 million and $7.9 million, respectively, and carried an accumulated deficit of $109.1 million. Management warns of continued losses and the need for “substantial additional funding” to advance its R&D and manufacturing programs.
Pipeline update: • INM-901 (Alzheimer’s disease): new pre-clinical data (24 Jun 2025) showed statistically significant reductions in neuro-inflammatory markers (NLRP3, IL-1β, IL-6, IL-2, KC/Gro). • INM-089 (dry-AMD) and INM-755 (epidermolysis bullosa) remain key assets; INM-755 completed Phase 2 with positive anti-itch signals; partnering discussions are ongoing. • BayMedica subsidiary continues B2B sales of rare cannabinoids and contributes modest revenue.
Status & risk designations: INM qualifies as an Emerging Growth Company and Smaller Reporting Company, allowing reduced disclosure and auditor attestation requirements. Management highlights delisting risk should the share price fall below Nasdaq’s minimum bid and emphasizes reliance on future equity or strategic transactions to fund operations.
Key takeaway: The S-1 does not introduce new capital for INM but sets the stage for significant potential share supply from a single holder. While recent pre-clinical data strengthen the Alzheimer’s program, the sizeable warrant overhang and ongoing cash burn heighten dilution and price-pressure risks for existing shareholders.
Barclays Bank PLC is issuing $452,000 of unsecured, unsubordinated Buffered Supertrack SM Notes linked to the price return of the Russell 2000 Index (RTY). The notes are part of the bank’s Global Medium-Term Notes, Series A and will be offered in $1,000 denominations on 30 Jun 2025, maturing 30 Dec 2027.
- Payout profile – If the index is flat or up at maturity, investors receive principal plus 2× upside, capped at a 31.35 % maximum return ($1,313.50 per $1,000 note).
- Downside buffer – First 10 % decline is fully protected. Below the 90 % Buffer Value (1,922.57), losses are linear: every additional 1 % drop erodes 1 % of principal, up to a 90 % loss.
- Key parameters: Initial Value 2,136.185; Upside Leverage 2.0; Buffer 10 %; CUSIP 06746BX71; Estimated value on pricing date $965.70 (≈3.4 % below issue price).
- Costs & liquidity: 2.75 % selling commission; no exchange listing; Barclays Capital intends, but is not obliged, to make a secondary market.
- Credit & regulatory risk: Payments depend on Barclays’ creditworthiness and are subject to the U.K. Bail-in Power, meaning principal could be written down or converted to equity during resolution.
- Tax & withholding: Issuer views the notes as prepaid forward contracts; U.S. tax treatment uncertain; Section 871(m) not expected to apply (delta ≠ 1).
The structure targets investors who can forgo coupons, accept a capped return, and tolerate meaningful equity and issuer risk in exchange for a modest downside buffer and enhanced—though limited—upside participation.
InMed Pharmaceuticals has announced promising new preclinical data for their drug candidate INM-901 on June 24, 2025. The research demonstrates significant reduction in inflammation in ex vivo models of neuroinflammation, strengthening the compound's potential as a therapeutic treatment for Alzheimer's disease.
Key points from the 8-K filing:
- The announcement falls under Regulation FD Disclosure (Item 7.01)
- The company is classified as an emerging growth company
- Common shares trade on Nasdaq under symbol INM
- The disclosure is being furnished rather than "filed" under SEC regulations
This development represents a significant milestone in InMed's neurodegenerative disease pipeline, though specific efficacy data and trial details were not disclosed in the filing. The news was signed off by President & CEO Eric A Adams.
FAQ
What is the current stock price of Inmed Pharmaceuticals (INM)?
What is the market cap of Inmed Pharmaceuticals (INM)?
What does InMed Pharmaceuticals Inc specialize in?
How does the company generate its revenue?
What are the core therapeutic areas of InMed?
How does InMed protect its innovations?
How is InMed different from other biopharmaceutical companies?
What key product candidates are under development?
